CL2016000838A1 - Combinación farmacéutica que comprende un inhibidor específico de histona desacetilasa 6 (hdac6) derivado de pirimidin hidroxiamida y un inmunomodulador (imid); y su uso para el tratamiento de mieloma múltiple. - Google Patents
Combinación farmacéutica que comprende un inhibidor específico de histona desacetilasa 6 (hdac6) derivado de pirimidin hidroxiamida y un inmunomodulador (imid); y su uso para el tratamiento de mieloma múltiple.Info
- Publication number
- CL2016000838A1 CL2016000838A1 CL2016000838A CL2016000838A CL2016000838A1 CL 2016000838 A1 CL2016000838 A1 CL 2016000838A1 CL 2016000838 A CL2016000838 A CL 2016000838A CL 2016000838 A CL2016000838 A CL 2016000838A CL 2016000838 A1 CL2016000838 A1 CL 2016000838A1
- Authority
- CL
- Chile
- Prior art keywords
- hdac6
- hydroxyamide
- imid
- immunomodulator
- pyrimidin
- Prior art date
Links
- 208000034578 Multiple myelomas Diseases 0.000 title abstract 2
- 206010035226 Plasma cell myeloma Diseases 0.000 title abstract 2
- CZSAQVUTTJIFQH-UHFFFAOYSA-N hydroxylamine pyrimidine Chemical compound ON.C1=CN=CN=C1 CZSAQVUTTJIFQH-UHFFFAOYSA-N 0.000 title abstract 2
- 239000002955 immunomodulating agent Substances 0.000 title abstract 2
- 229940121354 immunomodulator Drugs 0.000 title abstract 2
- 230000002584 immunomodulator Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000011427 Histone Deacetylase 6 Human genes 0.000 title 1
- 108010023925 Histone Deacetylase 6 Proteins 0.000 title 1
- 108010033040 Histones Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361889640P | 2013-10-11 | 2013-10-11 | |
| US201361911089P | 2013-12-03 | 2013-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016000838A1 true CL2016000838A1 (es) | 2016-11-25 |
Family
ID=52810182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016000838A CL2016000838A1 (es) | 2013-10-11 | 2016-04-11 | Combinación farmacéutica que comprende un inhibidor específico de histona desacetilasa 6 (hdac6) derivado de pirimidin hidroxiamida y un inmunomodulador (imid); y su uso para el tratamiento de mieloma múltiple. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20150105358A1 (OSRAM) |
| EP (1) | EP3054939A4 (OSRAM) |
| JP (4) | JP2016532667A (OSRAM) |
| KR (1) | KR20160060143A (OSRAM) |
| CN (1) | CN105722507A (OSRAM) |
| AU (1) | AU2014332147A1 (OSRAM) |
| CA (1) | CA2926808A1 (OSRAM) |
| CL (1) | CL2016000838A1 (OSRAM) |
| CR (1) | CR20160200A (OSRAM) |
| EA (1) | EA201690753A1 (OSRAM) |
| IL (1) | IL244923A0 (OSRAM) |
| MX (1) | MX2016004604A (OSRAM) |
| NI (1) | NI201600051A (OSRAM) |
| PE (1) | PE20161342A1 (OSRAM) |
| PH (1) | PH12016500649A1 (OSRAM) |
| SG (1) | SG11201602791RA (OSRAM) |
| WO (1) | WO2015054175A1 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2526093T (lt) | 2010-01-22 | 2016-10-10 | Acetylon Pharmaceuticals, Inc. | Grįžtamieji amido junginiai kaip baltymo deacetilazės inhibitoriai ir jų panaudojimo būdai |
| JP6041808B2 (ja) | 2010-11-16 | 2016-12-14 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 蛋白質脱アセチル化酵素抑制剤としてのピリミジン水酸基アミド化合物およびその利用方法 |
| HK1207403A1 (en) | 2012-04-19 | 2016-01-29 | Acetylon Pharmaceuticals, Inc. | Biomarkers to identify patients that will respond to treatment and treating such patients |
| US9145412B2 (en) | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
| US9403779B2 (en) * | 2013-10-08 | 2016-08-02 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and either Her2 inhibitors or PI3K inhibitors |
| EP3055299B1 (en) * | 2013-10-10 | 2021-01-06 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors |
| EP3054939A4 (en) * | 2013-10-11 | 2017-12-13 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deactylase inhibitors and immunomodulatory drugs |
| JP2016534069A (ja) | 2013-10-24 | 2016-11-04 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | Ｈｄａｃ６阻害剤での多嚢胞性疾患の治療 |
| US9949972B2 (en) | 2013-12-03 | 2018-04-24 | Acetylon Pharmaceuticals, Inc | Combinations of histone deacetylase inhibitors and immunomodulatory drugs |
| US9464073B2 (en) | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
| EP3166603B1 (en) | 2014-07-07 | 2020-02-12 | Acetylon Pharmaceuticals, Inc. | Treatment of leukemia with histone deacetylase inhibitors |
| CA2969790A1 (en) | 2014-12-05 | 2016-06-09 | University of Modena and Reggio Emilia | Combinations of histone deacetylase inhibitors and bendamustine |
| ES2816641T3 (es) | 2014-12-12 | 2021-04-05 | Regenacy Pharmaceuticals Inc | Derivados de piperidina en calidad de inhibidores de HDAC1/2 |
| WO2016200930A1 (en) | 2015-06-08 | 2016-12-15 | Acetylon Pharmaceuticals, Inc. | Methods of making protein deacetylase inhibitors |
| EP3303306B1 (en) | 2015-06-08 | 2020-02-12 | Acetylon Pharmaceuticals, Inc. | Crystalline forms of a histone deacetylase inhibitor |
| US11311540B2 (en) * | 2016-02-17 | 2022-04-26 | Acetylon Pharmaceuticals, Inc. | Increasing expression of interferon regulated genes with combinations of histone deacetylase inhibitors and immunomodulatory drugs |
| JP2019515909A (ja) | 2016-04-19 | 2019-06-13 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 慢性リンパ性白血病の治療を目的とするｈｄａｃ阻害剤単独またはｂｔｋ阻害剤との配合物 |
| AR109250A1 (es) | 2016-06-09 | 2018-11-14 | Acetylon Pharmaceuticals Inc | Métodos de uso y combinaciones farmacéuticas de inhibidores de hdac con inhibidores de proteínas bet |
| EP3496751B1 (en) | 2016-08-08 | 2022-10-19 | Acetylon Pharmaceuticals Inc. | Pharmaceutical combinations of histone deacetylase 6 inhibitors and cd20 inhibitory antibodies and uses thereof |
| KR102002581B1 (ko) * | 2016-10-04 | 2019-07-22 | 주식회사 종근당 | 혈액암 치료를 위한 hdac 저해제 및 프로테아좀 억제제 또는 면역조절성 약물을 포함하는 약학적 조합물 |
| JP7516047B2 (ja) * | 2016-11-23 | 2024-07-16 | アセチロン ファーマシューティカルズ インコーポレイテッド | ヒストン脱アセチル化酵素阻害剤とｃｄ３８阻害剤とを含む医薬組み合わせ物及びその使用方法 |
| JP7090611B2 (ja) * | 2016-11-23 | 2022-06-24 | アセチロン ファーマシューティカルズ インコーポレイテッド | ヒストン脱アセチル化酵素阻害剤とプログラム細胞死リガンド１（ｐｄ－ｌ１）阻害剤とを含む医薬組み合わせ物及びその使用方法 |
| CA3165424A1 (en) | 2019-12-20 | 2021-06-24 | Tenaya Therapeutics, Inc. | Fluoroalkyl-oxadiazoles and uses thereof |
| EP4326263A1 (en) | 2021-04-23 | 2024-02-28 | Tenaya Therapeutics, Inc. | Hdac6 inhibitors for use in the treatment of dilated cardiomyopathy |
| TW202308619A (zh) | 2021-05-04 | 2023-03-01 | 美商特納亞治療股份有限公司 | 用於治療代謝疾病和hfpef的hdac6抑制劑 |
| WO2025215092A1 (en) | 2024-04-10 | 2025-10-16 | Institut National de la Santé et de la Recherche Médicale | Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US8828392B2 (en) | 2005-11-10 | 2014-09-09 | Topotarget Uk Limited | Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent |
| LT2526093T (lt) * | 2010-01-22 | 2016-10-10 | Acetylon Pharmaceuticals, Inc. | Grįžtamieji amido junginiai kaip baltymo deacetilazės inhibitoriai ir jų panaudojimo būdai |
| JP6041808B2 (ja) * | 2010-11-16 | 2016-12-14 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 蛋白質脱アセチル化酵素抑制剤としてのピリミジン水酸基アミド化合物およびその利用方法 |
| JP6169076B2 (ja) * | 2011-07-20 | 2017-07-26 | ザ ジェネラル ホスピタル コーポレイション | 骨疾患の処置のためのヒストン脱アセチル化酵素６選択的阻害剤 |
| EP3054939A4 (en) * | 2013-10-11 | 2017-12-13 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deactylase inhibitors and immunomodulatory drugs |
-
2014
- 2014-10-07 EP EP14851888.9A patent/EP3054939A4/en not_active Withdrawn
- 2014-10-07 CN CN201480062094.3A patent/CN105722507A/zh active Pending
- 2014-10-07 MX MX2016004604A patent/MX2016004604A/es unknown
- 2014-10-07 SG SG11201602791RA patent/SG11201602791RA/en unknown
- 2014-10-07 US US14/508,072 patent/US20150105358A1/en not_active Abandoned
- 2014-10-07 EA EA201690753A patent/EA201690753A1/ru unknown
- 2014-10-07 CA CA2926808A patent/CA2926808A1/en not_active Abandoned
- 2014-10-07 AU AU2014332147A patent/AU2014332147A1/en not_active Abandoned
- 2014-10-07 JP JP2016521758A patent/JP2016532667A/ja active Pending
- 2014-10-07 CR CR20160200A patent/CR20160200A/es unknown
- 2014-10-07 KR KR1020167011860A patent/KR20160060143A/ko not_active Withdrawn
- 2014-10-07 WO PCT/US2014/059387 patent/WO2015054175A1/en not_active Ceased
- 2014-10-07 PE PE2016000490A patent/PE20161342A1/es not_active Application Discontinuation
-
2016
- 2016-04-05 IL IL244923A patent/IL244923A0/en unknown
- 2016-04-08 PH PH12016500649A patent/PH12016500649A1/en unknown
- 2016-04-11 NI NI201600051A patent/NI201600051A/es unknown
- 2016-04-11 CL CL2016000838A patent/CL2016000838A1/es unknown
-
2018
- 2018-11-30 JP JP2018225287A patent/JP7403950B2/ja active Active
-
2019
- 2019-11-15 US US16/684,809 patent/US20200323849A1/en not_active Abandoned
-
2021
- 2021-02-12 JP JP2021020680A patent/JP2021073314A/ja active Pending
-
2023
- 2023-10-26 JP JP2023184173A patent/JP2024010118A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7403950B2 (ja) | 2023-12-25 |
| EA201690753A1 (ru) | 2016-07-29 |
| PH12016500649A1 (en) | 2016-05-30 |
| US20150105358A1 (en) | 2015-04-16 |
| AU2014332147A1 (en) | 2016-05-05 |
| JP2021073314A (ja) | 2021-05-13 |
| IL244923A0 (en) | 2016-05-31 |
| JP2019052171A (ja) | 2019-04-04 |
| US20200323849A1 (en) | 2020-10-15 |
| CR20160200A (es) | 2016-08-29 |
| NI201600051A (es) | 2017-07-11 |
| EP3054939A1 (en) | 2016-08-17 |
| JP2024010118A (ja) | 2024-01-23 |
| MX2016004604A (es) | 2016-08-01 |
| PE20161342A1 (es) | 2016-12-31 |
| CA2926808A1 (en) | 2015-04-16 |
| EP3054939A4 (en) | 2017-12-13 |
| JP2016532667A (ja) | 2016-10-20 |
| CN105722507A (zh) | 2016-06-29 |
| SG11201602791RA (en) | 2016-05-30 |
| WO2015054175A1 (en) | 2015-04-16 |
| KR20160060143A (ko) | 2016-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016000838A1 (es) | Combinación farmacéutica que comprende un inhibidor específico de histona desacetilasa 6 (hdac6) derivado de pirimidin hidroxiamida y un inmunomodulador (imid); y su uso para el tratamiento de mieloma múltiple. | |
| CL2016001358A1 (es) | Combinaciones de inhibidores de histona deacetilasa y fármacos inmunomoduladores | |
| CL2016000925A1 (es) | Inhibidores de bromodominio | |
| IL282090A (en) | Tyk2 inhibitors and uses thereof | |
| CO2017002532A2 (es) | Indazoles sustituidos con bencilo como inhibidores de bub1 | |
| MX2017014299A (es) | Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos. | |
| CL2018000687A1 (es) | Nuevos compuestos bicíclicos como inhibidores de atx. | |
| UY36153A (es) | ?inhibidores de la fosfoinosítido 3-quinasa delta para su uso en el tratamiento de una enfermedad cutánea inmunoampollosa mediada por autoanticuerpos? | |
| CL2016002169A1 (es) | Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados. | |
| MX2017001553A (es) | Derivados de heterociclico opcionalmente condensados de pirimidina utiles para el tratamiento de enfermedades inflamatorias, metabolicas oncologicas y autoinmunitarias. | |
| MX2015012558A (es) | Inhibidores de histona desacetilasa. | |
| EP3624804A4 (en) | HISTONE DEACETYLASE INHIBITORS (HDAC) | |
| CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
| EP3586873A4 (en) | APPLICATION OF A SPECIFIC ENZYMATIC INHIBITOR FOR CENTRAL NERODE SYSTEM NEURODEGENERATION | |
| MX2017001352A (es) | Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2). | |
| MA47305A (fr) | Inhibiteurs bicycliques d'histone désacétylase | |
| MX374654B (es) | Compuestos útiles para inhibir ror-gamma-t. | |
| CO2019006113A2 (es) | Pulverizador | |
| CL2015002113A1 (es) | Compuestos de azetidinloxifenilpirrolidina | |
| MX2017014300A (es) | Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos. | |
| EP3397617A4 (en) | HISTONDEMETHYLASEINHIBITOREN | |
| BR112017028139A2 (pt) | inibidores de histona desacetilase | |
| IL272479B1 (en) | Bicyclic inhibitors of histone deacetylase | |
| AR100289A1 (es) | Formas de un inhibidor de pi3k | |
| EP3600295A4 (en) | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS |